Biosimilars | Overview & Forecast | G7 | 2016

Biologics in oncology, immunology, nephrology and endocrinology generated over $70 billion in 2015, nearly all attributed to branded biologics. As more branded agents lose patent protection and more biosimilars enter the market, branded biologics are expected to lose considerable market share, both by declining use but also price reductions. We present our forecasts for 36 reference brands and their biosimilars, over the 2015-2025 period by therapeutic area, molecule, and region.